Find the lowest price from 7,500+ FDA-registered pharmacies. Save up to 90%.
⭐ 4.7/5 Customer Rating
🏅 FDA-Registered Pharmacies
Prevents mast cells from degranulating — stopping the release of histamine, leukotrienes, and other inflammatory mediators before they trigger symptoms.
Blocks histamine H1 receptors directly at target tissues — a second line of action that manages symptoms even when some mediator release occurs.
Rapamycin (sirolimus) is the most studied pharmacological intervention for extending lifespan in laboratory models. At low, intermittent doses it is increasingly prescribed off-label for longevity, immune modulation, and age-related disease prevention. Compounding allows the precise low-dose formulations that longevity protocols require.
Search 7,500+ licensed pharmacies to find the best value, closest location, and fastest turnaround for
.
Rapamycin inhibits mTOR (mechanistic target of rapamycin), a master regulator of cell growth, metabolism, and aging. By intermittently suppressing mTOR Complex 1 (mTORC1), low-dose rapamycin activates autophagy (cellular cleanup), reduces senescent cell burden, improves immune function, and mimics the cellular effects of caloric restriction — the most validated lifespan extension intervention.
FDA-approved Rapamune comes in 1mg and 2mg tablets designed for daily transplant immunosuppression. Longevity protocols typically use 3–6mg once weekly — a dose and schedule not available commercially. Compounding pharmacies prepare custom-dose capsules (1mg, 2mg, 3mg, 5mg, 6mg) optimized for intermittent dosing protocols. Topical rapamycin for skin aging is also only available through compounding.
Rapamycin (sirolimus) has emerged as the most promising pharmacological candidate for human longevity. Originally FDA-approved in 1999 for preventing organ transplant rejection, its anti-aging properties were discovered when researchers found it consistently extended lifespan in mice — even when started late in life.
The key insight driving clinical interest is that rapamycin's longevity effects occur at doses far below those used for immunosuppression. Low-dose, intermittent rapamycin (typically once weekly) appears to selectively inhibit mTORC1 while sparing mTORC2, producing immune enhancement rather than suppression — a critical distinction from transplant dosing.
Compounded rapamycin has become one of the fastest-growing categories in longevity medicine, prescribed by physicians who specialize in healthspan optimization and age-related disease prevention.
mTOR Inhibition and Autophagy
Rapamycin binds to the intracellular protein FKBP12, forming a complex that directly inhibits mTOR Complex 1 (mTORC1). mTORC1 is a nutrient-sensing kinase that promotes cell growth and protein synthesis when nutrients are abundant. By inhibiting mTORC1, rapamycin activates autophagy — the cellular recycling process that clears damaged proteins, dysfunctional mitochondria, and senescent cells. This mimics the molecular effects of caloric restriction.
Immune Modulation at Low Doses
At transplant-level daily doses, rapamycin is immunosuppressive. However, at low intermittent doses (weekly), it paradoxically enhances immune function. A landmark 2014 study by Mannick et al. showed that low-dose mTOR inhibition improved elderly patients' response to influenza vaccination by approximately 20%. This immune-enhancing effect is a key rationale for longevity dosing.
Senolytic and Anti-inflammatory Effects
Rapamycin reduces the senescence-associated secretory phenotype (SASP) — the inflammatory signals emitted by senescent (zombie) cells that drive age-related tissue dysfunction. It also reduces chronic low-grade inflammation (inflammaging), a hallmark of biological aging.
Prescribed off-label for patients seeking evidence-based longevity interventions:
BIND THIS TO: Mechanism Text CMS field (Rich Text). Then delete this paragraph and add a Rich Text element instead.
Transplant rejection prevention (FDA-approved indication), lymphangioleiomyomatosis (LAM), tuberous sclerosis complex (TSC), coronary stent coating, periodontal disease (emerging), autoimmune conditions (investigational)
⚠️ Dosing should be determined by your prescriber. The information below is general guidance only.
Common longevity protocols:
Conservative: 3mg once weekly
Standard: 5–6mg once weekly
Aggressive: 6mg once weekly with periodic 2-week drug holidays every 6–8 weeks
Topical (skin aging):
0.1–1% cream applied to face 2–3x per week
Dosing is highly individualized. Trough levels and lab monitoring guide dose adjustments. Your prescriber will determine the appropriate protocol.
Most protocols start at 3mg weekly and assess tolerability and labs at 4–8 weeks before increasing. Mouth sores (aphthous ulcers) are the most common early side effect and often resolve with continued use or dose adjustment. Taking rapamycin with a high-fat meal increases absorption and reduces GI side effects. Periodic drug holidays (1–2 weeks off every 6–8 weeks) are incorporated in many protocols to allow full mTORC2 recovery.
Oral Capsules (Custom Dose) — The most common form for longevity use. Compounded in precise doses (1mg, 2mg, 3mg, 5mg, 6mg) that aren't available commercially in all strengths. Capsules allow exact weekly dosing.
Oral Solution — Liquid rapamycin for patients who have difficulty swallowing capsules or need micro-dose titration. Allows very precise dose adjustments.
Topical Cream — Compounded at 0.1–1% concentration for facial application. Used for skin aging, sun damage, and age spots. Applied 2–3 times per week. Only available through compounding.
At low intermittent (longevity) doses:
Important distinctions: Side effects at weekly longevity doses are significantly milder than daily transplant doses. Most are manageable with dose adjustment or temporary drug holidays. Lipid changes are the most persistent effect and may require monitoring or treatment.
Rapamycin (sirolimus) is FDA-approved as Rapamune for transplant rejection prevention. All longevity and anti-aging uses are off-label. Compounded rapamycin is a 503A patient-specific preparation. It is not a controlled substance. Prescribers should monitor labs regularly and patients should report any signs of infection, unusual bruising, or mouth sores. Rapamycin has known drug interactions — patients must disclose all medications to their prescriber.
Low-dose, intermittent rapamycin (e.g., 5–6mg once weekly) has a different safety profile than daily transplant dosing. Multiple physician-led protocols report favorable safety at these doses, with lipid changes and mouth sores as the most common side effects. However, long-term human longevity data is still being collected. Regular monitoring of labs (CBC, lipids, metabolic panel) is required.
Transplant patients take 2–5mg daily (continuous immunosuppression). Longevity protocols typically use 3–6mg once per week with periodic drug holidays. This intermittent schedule selectively inhibits mTORC1 while allowing mTORC2 recovery, producing immune enhancement rather than suppression.
Compounded rapamycin typically costs $30–$120 per month depending on the dose and pharmacy. This is often significantly less than brand-name Rapamune. Compounding Finder helps you compare options from multiple licensed pharmacies.
Most prescribers monitor CBC with differential, comprehensive metabolic panel, fasting lipids, fasting glucose/HbA1c, and rapamycin trough levels. Labs are typically checked at baseline, 4–8 weeks after starting, and periodically thereafter.
Yes. Topical rapamycin (typically 0.1–1% cream) is being studied and used off-label for skin aging, facial rejuvenation, and reduction of age spots. It is only available through compounding pharmacies.
Yes. Rapamycin is a prescription medication. A licensed healthcare provider must evaluate your health status, order baseline labs, and monitor your treatment.
1. Mannick JB, et al. mTOR inhibition improves immune function in the elderly. Sci Transl Med. 2014;6(268):268ra179.
2. Blagosklonny MV. Rapamycin for longevity: opinion article. Aging (Albany NY). 2019;11(19):8048-8067.
3. Harrison DE, et al. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature. 2009;460(7253):392-395.
4. Kraig E, et al. A randomized control trial to establish the feasibility and safety of rapamycin treatment in an older human cohort: Immunological, physical performance and cognitive effects. Exp Gerontol. 2018;105:53-69.
Submit a quote request to find the lowest price. Quotes delivered to your inbox.
Find Lowest Price.png){kind=spacer}
Prevents mast cells from degranulating — stopping the release of histamine, leukotrienes, and other inflammatory mediators before they trigger symptoms.
